IL2 and systemic lupus erythematosus: Over the last decade, treatment of patients with systemic lupus erythematosus (SLE) with low-dose interleukin-2 (IL-2) has emerged as a promising new therapeutic modality for the amelioration of disease manifestations without significant side effects.